Heritage Pharmaceuticals Initiates A Nationwide Voluntary Recall Of Colistimethate For Injection USP, 150 Mg And Rifampin For Injection USP, 600 Mg/Vial Due To A Lack Of Sterility Assurance

EATONTOWN, N.J., Feb. 25, 2015 /PRNewswire/ -- Heritage Pharmaceuticals Inc. (Heritage) today announced the voluntary nationwide recall of ten (10) lots of Colistimethate for Injection, USP, 150 mg Single-Dose vial (NDC 23155-193-31) and three (3) lots of Rifampin for Injection, USP, 600 mg Single-Dose vial (NDC 23155-340-31) manufactured by Emcure Pharmaceuticals Ltd. and distributed by Heritage. Both products are sold in single vial mono-cartons in case packs of ten (10). Heritage has initiated this voluntary recall of Colistimethate for Injection, USP, 150 mg Single-Dose vial and Rifampin for Injection USP, 600 mg Single-Dose vial to the user level due to FDA observations pertaining to aseptic and GMP practices at the manufacturer's site potentially impacting product sterility.

Intravenous administration of  non-sterile injection products to a normally sterile site may result in a site-specific or systemic infection, which in turn may cause hospitalization, significant morbidity (permanent organ damage), or fatal outcome. To date, Heritage is not aware of any adverse patient events resulting from the use of the subject product lots.

The lot numbers with expiry date being recalled are:

The products were distributed to hospitals, wholesalers and distributors nationwide from December 2012 through January 2015 (Colistimethate) and from October 2014 through January 2015 (Rifampin).  Colistimethate is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacteria.  Rifampin is indicated for the treatment of all forms of tuberculosis.

Customers are being notified by fax, email, UPS, and/or certified mail that includes arrangements for return of all recalled product.  Customers have been instructed to examine their inventory immediately and to quarantine, discontinue distribution of, and return the recalled lots of product.  Customers who may have further distributed these products have been requested to identify their customers and notify them at once of this product recall. 

Any questions about returning unused product should be directed to the customer call center at (866) 901-1230 M-F 9am-5pm EST.  Healthcare workers who have medical questions about Colistimethate for Injection, USP, 150 mg base/vial and Rifampin for Injection USP, 600 mg/vial may contact Heritage Medical Affairs (732-429-1000, Ext. 101) M-F 9am-5pm EST.  

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

Adverse reactions or quality problems experienced with the use of these products may be reported to the FDA's MedWatch Adverse Event Report Program either online, by regular mail or by fax.

• Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
• Regular mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

About Heritage Pharmaceuticals Inc.
Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development, licensing, sales and marketing of prescription pharmaceutical products.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/heritage-pharmaceuticals-initiates-a-nationwide-voluntary-recall-of-colistimethate-for-injection-usp-150-mg-and-rifampin-for-injection-usp-600-mgvial-due-to-a-lack-of-sterility-assurance-300040871.html

SOURCE Heritage Pharmaceuticals Inc.